Novavax Will Seek a Combo Vaccine for Flu and COVID-19
While Novavax (NASDAQ: NVAX) is racing to bring its coronavirus vaccine candidate to market as fast as possible, the company is also planning for a post-pandemic future. "I am excited about the potential to develop a combined influenza/COVID-19 vaccine for use after the pandemic," said Chief Executive Officer Stanley Erck in a news release Tuesday to announce the formation of a leadership team to move its flu vaccine candidate, Nanoflu, through the regulatory approval process.
Back in March, the vaccine specialist found success with its phase 3 trial for Nanoflu, but that good news was somewhat swamped by the urgency of finding a vaccine for COVID-19. Novavax's candidate in that effort, NVX-CoV2373, has been zooming through the development process at a rapid pace, and is being tested in multiple trials, including a phase 2 trial in Australia and the U.S., a phase 2 trial in South Africa, and a 10,000 person phase 3 trial in the U.K. Another phase 3 trial involving 30,000 volunteers is planned for the U.S.
Image source: Getty Images
Source Fool.com
